There are no approved treatments for nonrelapsing secondary progressive multiple sclerosis. In a phase 3, double-blind, placebo-controlled, event-driven trial, we randomly assigned participants ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed.

Stem cells from donated placentas appear safe and may help ease secondary progressive MS, a small open-label Phase 1 clinical ...

The following is a summary of “Secondary progression activity monitoring in MS despite an early highly active treatment the ...

"With no treatment options currently available for the broad population of patients with secondary progressive multiple sclerosis, tolebrutinib has demonstrated its ability to delay disability by ...

Cognitive symptoms, mood disorders, and fatigue manifest differently in relapsing-remitting vs. progressive forms of MS, a ...

There isn’t enough evidence to back the use of Novartis Mayzent for secondary progressive multiple sclerosis on the NHS (SPMS), despite a desperate lack of treatments for this form of the ...

The NHS has shared a tweet to raise awareness of multiple sclerosis (MS), an incurable condition that affects the central ...